APLS - Apellis Pharmaceuticals, Inc.
Chart Events
Price Crosses Moving Average
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 34.01 |
| Open | 33.82 |
| Bid | 31.09 x 1300 |
| Ask | 34.00 x 1300 |
| Day's Range | 32.34 - 33.82 |
| 52 Week Range | 16.85 - 45.04 |
| Volume | 469,988 |
| Avg. Volume | 1,042,804 |
| Market Cap | 2.543B |
| Beta (5Y Monthly) | 1.33 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -6.39 |
| Earnings Date | Jul 29, 2020 - Aug 03, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 54.00 |
Fair Value
Related Research
- GlobeNewswire
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Apellis Pharmaceuticals, Inc. (APLS), a global biopharmaceutical company pioneering targeted C3 therapies, today announced that the company approved the grant of an equity award to a new employee with a grant date of May 26, 2020, as an equity inducement award outside of the company's 2017 Stock Incentive Plan and material to the employee’s acceptance of employment with the company. The equity award was approved on April 30, 2020, in accordance with Nasdaq Listing Rule 5635(c)(4). The employee received an option to purchase 23,216 shares of Apellis common stock.
- GlobeNewswire
Apellis Initiates Phase 1/2 Study of APL-9 in Patients with Severe COVID-19
Apellis Pharmaceuticals, Inc. (APLS), a global biopharmaceutical company pioneering targeted C3 therapies, today announced that the company has initiated a Phase 1/2 clinical study of APL-9, an investigational C3 inhibitor designed for acute interventions, in COVID-19 patients with respiratory failure including acute respiratory distress syndrome (ARDS). In COVID-19, complement activation has also been found to be strongly associated with organ failure and thrombotic events, which involve the abnormal formation of blood clots and are an emerging cause of mortality in COVID-19 patients.2,3,4 Apellis initiated the Phase 1/2 study following preliminary results from its ongoing, non-interventional study in patients with ARDS secondary to COVID-19, which showed a substantial increase in the activation of the complement cascade.
- GlobeNewswire
Apellis Announces Plans to Submit NDA for Pegcetacoplan in Paroxysmal Nocturnal Hemoglobinuria (PNH)
Apellis Pharmaceuticals, Inc. (APLS), a global biopharmaceutical company pioneering targeted C3 therapies, today announced plans to submit a New Drug Application (NDA) for pegcetacoplan for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) in the second half of 2020. Based on feedback from the U.S. Food and Drug Administration (FDA) during a pre-NDA meeting to discuss the registration strategy for pegcetacoplan, Apellis plans to submit the NDA with results from the Phase 3 PEGASUS trial comparing pegcetacoplan to eculizumab in patients with PNH.
- GlobeNewswire
Apellis to Present Pivotal Paroxysmal Nocturnal Hemoglobinuria (PNH) Data at 25th EHA Annual Congress
Results from positive Phase 3 PEGASUS study in PNH selected for oral presentation at the 2020 European Hematology Association CongressPEGASUS showed superiority of pegcetacoplan.
- GlobeNewswire
Apellis Pharmaceuticals to Present at the BofA Securities 2020 Health Care Conference
Apellis Pharmaceuticals, Inc. (APLS) a global biopharmaceutical company pioneering targeted C3 therapies, today announced that the company will present at the BofA Securities 2020 Health Care Conference on Thursday, May 14, 2020 at 8:20 a.m. ET. The conference will be held in a virtual meeting format. Cedric Francois, M.D., Ph.D., co-founder and chief executive officer of Apellis, will participate in a fireside chat.
- GlobeNewswire
Apellis Pharmaceuticals Announces Private Placement of Convertible Senior Notes
Apellis Pharmaceuticals, Inc. (APLS), a global biopharmaceutical company pioneering targeted C3 therapies, today announced that it had entered into subscription agreements with a number of institutional investors for a private placement of $300.0 million aggregate principal amount of 3.500% convertible senior notes due 2026 (the “notes”) for an aggregate purchase price of $328.9 million. The private placement is expected to close on May 12, 2020, subject to satisfaction of customary closing conditions. The notes issuance is a reopening of, and will form a single series with, and have the same terms as, Apellis’ $220 million aggregate principal amount of 3.500% convertible senior notes due 2026 (the “existing notes”) issued on September 16, 2019, but will have a different issue date, issue price, CUSIP number and different restrictions on transfer.
- GlobeNewswire
Apellis Pharmaceuticals Reports First Quarter 2020 Financial Results
Full Enrollment of Two Phase 3 Trials in Geographic Atrophy Expected in the Second Quarter of 2020Meetings with US and EU Regulators to Discuss Submissions in Paroxysmal.
- GlobeNewswire
Apellis Reports Analysis from Phase 1b Geographic Atrophy Study
Apellis Pharmaceuticals, Inc. (APLS), a global biopharmaceutical company pioneering targeted C3 therapies, today announced early data from the Phase 1b APL2-103 study of pegcetacoplan (APL-2) in patients with advanced geographic atrophy (GA) and low vision. The study, which enrolled 12 patients, was initiated to assess the safety of the Phase 3 formulation of pegcetacoplan (15mg/0.1mL). The analysis of APL2-103 has shown that the Phase 3 formulation was well tolerated over 12 months of treatment.
- Insider Monkey
Hedge Funds Have Never Been This Bullish On Apellis Pharmaceuticals, Inc. (APLS)
We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was trading at the 3150 level. We also told you to short the market and buy […]
- GlobeNewswire
Paul Fonteyne Joins Apellis Board of Directors
Apellis Pharmaceuticals, Inc. (APLS), a global biopharmaceutical company pioneering targeted C3 therapies, today appointed Paul Fonteyne to its Board of Directors. Mr. Fonteyne’s appointment expands the Board to six directors, five of whom are independent. Mr. Fonteyne brings more than three decades of experience in the biopharmaceutical industry, including leadership roles in the United States and globally with Boehringer-Ingelheim, one of the world's leading pharmaceutical companies.
- GlobeNewswire
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results
Positive Top-line Results Announced from Head-to-Head Phase 3 PEGASUS Trial of Pegcetacoplan (APL-2) Compared to Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria.
- GlobeNewswire
Apellis Pharmaceuticals to Present at the 40th Annual Cowen Health Care Conference
WALTHAM, Mass., Feb. 26, 2020 -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company pioneering targeted C3 therapies, today announced that the.
- American City Business Journals
CEO council reveals innovation center location, plans international summit
Some of Louisville's most prominent and influential health care executives are members of this organization. It's moving forward with two strategic initiatives.
- American City Business Journals
Alexion pushes 'high-risk, high-reward' ALS strategy amid competitive pressure
With competition encroaching, Alexion executives are pushing plans to more than double the company’s product portfolio in the next three years, including at least one “high risk, high reward” drug candidate.
- American City Business Journals
Apellis Pharmaceuticals' stock offering closes $50M higher than expected
The former Louisville-area company sold about 1.4 million more shares that were part of an option held by financial firms involved with the public stock offering.
- GlobeNewswire
Apellis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Option to Purchase Additional Shares
WALTHAM Mass., Jan. 13, 2020 -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a global biopharmaceutical company pioneering targeted C3 therapies, today announced the closing of.
- Insider Monkey
Apellis Pharmaceuticals, Inc. (APLS) vs. Hedge Fund Favorites in 2019
We are still in an overall bull market and many stocks that smart money investors were piling into surged in 2019. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 57% each. Hedge funds' top 3 stock picks returned 45.7% last year and beat the S&P 500 ETFs by […]
- Investor's Business Daily
Stock Market Rally Powers Higher Despite Iran Tensions; Tesla, Boeing, Costco, Beyond Meat In Focus: Weekly Review
The stock market rally hit new highs despite an Iran missile attack. Tesla, Costco and Beyond Meat rallied. A Boeing 737 crash was just one of several big headlines for the aerospace giant.
- American City Business Journals
Apellis Pharmaceuticals is planning to raise $350M — here's how
Apellis Pharmaceuticals Inc. is hoping to garner hundreds of millions of dollars in its latest public stock offering. The late-stage biopharmaceutical company disclosed late Wednesday that it will issue 9.5 million shares of common stock at $37 per share for potential gross proceeds of $351.5 million before certain deductions related to the public offerings. Citigroup Global Markets Inc., J.P. Morgan Securities LLC and Evercore Group LLC are joint bookrunning managers and underwriters of the offering.
- GlobeNewswire
Apellis Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Apellis Pharmaceuticals, Inc. (APLS), a global biopharmaceutical company pioneering targeted C3 therapies, today announced the pricing of its underwritten public offering of 9.5 million shares of its common stock at a public offering price of $37.00 per share, for total gross proceeds of $351.5 million, before deducting underwriting discounts and commissions and expenses payable by Apellis. All of the shares in the offering are being sold by Apellis. In addition, Apellis has granted the underwriters a 30-day option to purchase up to 1.425 million additional shares of its common stock at the public offering price, less the underwriting discount and commissions.
- Zacks
Biotech Stock Roundup: Updates From INCY & EXEL, APLS & LIFE Surge on Positive Data
A low-key week for the biotech sector, with a few pipeline and regulatory updates.
- Benzinga
The Daily Biotech Pulse: Verastem In-Licenses Chughai's Tumor Drug, Midatech Surges On Positive Study Results
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Jan. 7) Apellis Pharmaceuticals Inc (NASDAQ: APLS ) (announced ...
- Zacks
Apellis' (APLS) PNH Drug Betters Alexion's Soliris in Study
Apellis Pharmaceuticals' (APLS) experimental drug pegcetacoplan outperformed Alexion's blockbuster medicine, Soliris, in a phase III head-to-head study. Shares soar.
- Investor's Business Daily
This Biotech Just Topped Alexion's Biggest Moneymaker — And Rocketed
Shares of Apellis Pharmaceuticals rocketed Tuesday after the biotech company's experimental drug outperformed Alexion Pharmaceuticals' blockbuster, Soliris, in a head-to-head test.
- GlobeNewswire
Apellis Pharmaceuticals Announces Proposed Public Offering of Common Stock
Apellis Pharmaceuticals, Inc. (APLS), a global biopharmaceutical company pioneering targeted C3 therapies, today announced that it has commenced an underwritten public offering of 7,000,000 shares of its common stock. All of the shares are being offered by Apellis. In addition, Apellis expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock sold in the public offering.
